Mirati Therapeutics. has filed a patent for compounds that inhibit the activity of Son of sevenless homolog 1 (SOS1), which could be used in the treatment of cancer. The patent also covers pharmaceutical compositions and methods of using these compounds. The compounds are defined by a specific chemical formula and can be in the form of a salt. GlobalData’s report on Mirati Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Mirati Therapeutics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Mirati Therapeutics, Cancer treatment biomarkers was a key innovation area identified from patents. Mirati Therapeutics's grant share as of September 2023 was 33%. Grant share is based on the ratio of number of grants to total number of patents.

A recently filed patent (Publication Number: US20230312482A1) describes a compound of Formula (I) and its pharmaceutically acceptable salts. The compound has various substituents and can be used in pharmaceutical compositions for inhibiting SOS1 activity in cells. The compound can also be used in methods for treating cancer, particularly Ras family-associated cancers and SOS1-associated cancers.

The compound of Formula (I) described in the patent has a wide range of substituents, including hydrogen, hydroxyl, alkyl, alkoxy, amino groups, and various cyclic and aromatic groups. The compound can exist as a salt, which is pharmaceutically acceptable. The patent claims cover different variations of the compound, depending on the substituents present.

The patent also describes the use of the compound in pharmaceutical compositions. These compositions contain a therapeutically effective amount of the compound, along with a pharmaceutically acceptable excipient. The compositions can be used to inhibit SOS1 activity in cells, particularly in cells harboring activating mutations in RAS family-member genes, SOS1 genes, or NF-1 or NF-2 genes. Inhibition of SOS1 activity can be beneficial in treating cancer.

The patent further claims methods for treating cancer using the compound of Formula (I). The compound can be administered to patients with cancer in a therapeutically effective amount, either alone or in combination with other pharmaceutical ingredients. The dosage range for the compound is between about 0.01 to 300 mg/kg per day, with a preferred range of 0.1 to 100 mg/kg per day. The patent specifically mentions various types of cancers that can be treated, including cardiac, lung, gastrointestinal, genitourinary tract, liver, biliary tract, bone, nervous system, gynecological, hematologic, skin, and adrenal gland cancers.

The patent also highlights the use of the compound in treating Ras family-associated cancers and SOS1-associated cancers. Ras family-associated cancers include those associated with mutations in KRas, HRas, or NRas genes, such as non-small cell lung cancer and pancreatic cancer. SOS1-associated cancers include those associated with mutations in the SOS1 gene, such as lung adenocarcinoma, embryonal rhabdomyosarcoma, Sertoli cell testis tumor, and granular cell tumors of the skin. The compound of Formula (I) can be effective in inhibiting the activity of these cancer-associated proteins and potentially treating these types of cancers.

Overall, the patent describes a compound of Formula (I) and its use in pharmaceutical compositions and methods for treating cancer. The compound has a wide range of substituents and can be effective in inhibiting SOS1 activity in cells, particularly in Ras family-associated cancers and SOS1-associated cancers. Further research and development based on this patent may lead to new treatments for these types of cancers.

To know more about GlobalData’s detailed insights on Mirati Therapeutics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies